Primary Prevention
Population Subgroups: Women, Age & >75 Years, Race, and Ethnicity
Bile Acid Sequestrants
Nonstatins- Evolving Role in ASCVD Prevention
Risk Assessment: Primary Prevention LDL-C < 190 mg/dL
Primary Prevention- No Diabetes and LDL-C <190 mg/dL
Primary Prevention- Diabetes
Fewer US adults suggested for statin therapy for primary prevention by new risk calculator
Fewer U.S. adults aged 40 to 75 years are eligible for statin therapy for primary CVD prevention in the new PREVENT risk calculator compared with the older Pooled Cohort Equation, researchers reported.
Bempedoic acid receives broader indications from FDA
Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.
CMS risk reduction program lowered first-time heart attacks, strokes without raising costs
Data show CMS’ Million Hearts CVD Risk Reduction Model, which provided payments for CVD risk assessment and reduction, reduced incidence of first-time MIs and strokes over 5 years without significant changes in Medicare spending.
Statins for primary prevention provide similar protection among older vs. younger adults
Older individuals appeared to derive similar magnitude of LDL lowering and CV risk reduction from statin therapy initiation vs. younger patients, according to data from a large Danish study.